The quarter cleared a fairly modest consensus bar by a wide margin. Published expectations were approximately $660.9 million of revenue and $(0.52) of EPS; Natera delivered $752.8 million and $(0.47), respectively. That is roughly a 14% revenue beat and a five-cent EPS beat, making this more than an in-line report.
| Metric | Q2 2026 | Q2 2025 | Published expectation |
|---|---|---|---|
| Total revenue | $752.8M (Income Statement) | $546.6M (Income Statement) | ~$660.9M |
| Revenue growth | 37.7% (Financial Highlights) | — | — |
| Net loss per share | $(0.47) (Income Statement) | $(0.74) (Income Statement) | $(0.52) |
| Gross margin | 64.5% (Financial Highlights) | 63.4% (Financial Highlights) | — |
| Tests reported | 985,500 (Operating metrics) | 812,900 (Operating metrics) | — |
| Oncology tests processed | 296,700 (Operating metrics) | 188,800 (Operating metrics) | — |
| Cash, cash equivalents and restricted cash | $1,091.5M (Balance Sheet) | $1,076.1M at Dec. 31, 2025 (Balance Sheet) | — |
The strongest underlying signal is volume, especially oncology. Tests reported rose 21.2% year over year, while oncology tests processed jumped 57.2%, with clinical MRD units increasing by 34,000 sequentially—the largest sequential increase cited in the filing (Operating metrics). Revenue grew faster than reported-test volume, indicating help from pricing, mix, or revenue recognition as well as demand (Financial Highlights).
Headline gross margin is better, but the quarter received a meaningful accounting lift. Natera recognized a $52.3 million revenue-accrual estimate change in Q2, equal to 2.7% of revenue, which increased reported revenue and gross profit (Financial Highlights). Excluding these accrual changes, management says non-GAAP gross margin improved only about 0.5 percentage points sequentially (Gross margin reconciliation). That still indicates incremental progress, but the 64.5% headline margin overstates the clean quarter-to-quarter improvement.
Profitability improved despite heavier investment, but Natera remains materially loss-making. Operating loss narrowed to $75.8 million from $110.4 million, and net loss narrowed to $67.0 million from $100.9 million (Income Statement). However, research and development expense rose 55.8% year over year to $228.1 million, while total operating expenses increased 21.5% to $555.3 million (Income Statement; Operating expenses). The revenue beat therefore translated into better losses, not breakeven economics.
The outlook is constructive but not clearly upgraded by this filing. Natera projects 2026 revenue of $2.85 billion to $2.91 billion, gross margin of approximately 64% to 66%, and positive cash flow (2026 outlook). Because the filing does not state whether these ranges were raised, reaffirmed, or newly introduced, the quarter supports the outlook but does not establish a separate guidance beat. Net: a significant positive surprise on revenue, EPS, and operating momentum, tempered by the accrual-driven margin boost and continued substantial spending.
Read the original 8-K on SEC EDGAR ↗